Data Insights

AST-001 by Ascentawits Pharmaceuticals for Esophageal Cancer: Likelihood of Approval

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AST-001 in Esophageal Cancer

Data Insights

AST-001 by Ascentawits Pharmaceuticals for Rectal Cancer: Likelihood of Approval

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Rectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AST-001 in Rectal Cancer

Data Insights

AST-001 by Ascentawits Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - AST-001 in Non-Small Cell Lung Cancer

Data Insights

AST-001 by Ascentawits Pharmaceuticals for Renal Cell Carcinoma: Likelihood of Approval

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Renal Cell Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AST-001 in Renal Cell Carcinoma

Data Insights

AST-001 by Ascentawits Pharmaceuticals for Glioma: Likelihood of Approval

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Glioma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - AST-001 in Glioma

Data Insights

AST-001 by Ascentawits Pharmaceuticals for Solid Tumor: Likelihood of Approval

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AST-001 in Solid Tumor

Data Insights

AST-001 by Ascentawits Pharmaceuticals for Hepatocellular Carcinoma: Likelihood of Approval

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AST-001 in Hepatocellular Carcinoma

Data Insights

AST-001 by Ascentawits Pharmaceuticals for Gastric Cancer: Likelihood of Approval

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AST-001 in Gastric Cancer

Data Insights

AST-001 by Ascentawits Pharmaceuticals for Pancreatic Cancer: Likelihood of Approval

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AST-001 in Pancreatic Cancer

Data Insights

AST-001 by Ascentawits Pharmaceuticals for Colon Cancer: Likelihood of Approval

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Colon Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AST-001 in Colon Cancer

Data Insights

AST-001 by Ascentawits Pharmaceuticals for Prostate Cancer: Likelihood of Approval

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Prostate Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AST-001 in Prostate Cancer

Data Insights

AST-001 by Ascentawits Pharmaceuticals for Breast Cancer: Likelihood of Approval

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Breast Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AST-001 in Breast Cancer